modelA10AC04

Diagram of A10AC04

Extends from Pharmacokinetic.Models.PK_1C.

Information

name:InsulinLispro
ATC code:A10AC04
route:subcutaneous
compartments:1
dosage:10mg
volume of distribution:0.23L
clearance:1.2L/h
other parameters in model implementation

Insulin lispro is a rapid-acting human insulin analog used to improve glycemic control in patients with diabetes mellitus. It acts quickly to lower blood glucose levels and is typically administered immediately before meals. Insulin lispro is approved and widely used in current diabetic management, both for type 1 and type 2 diabetes.

Pharmacokinetics

Pharmacokinetic parameters reported for healthy adult subjects after single subcutaneous injection.

References

  1. de la Peña, A, et al., & Ignaut, DA (2015). Subcutaneous Injection Depth Does Not Affect the Pharmacokinetics or Glucodynamics of Insulin Lispro in Normal Weight or Healthy Obese Subjects. Journal of diabetes science and technology 9(4) 824–830. DOI:10.1177/1932296815573865 PUBMED:https://pubmed.ncbi.nlm.nih.gov/25697717

  2. Chao, M, et al., & Ning, G (2010). Bioequivalence between two human insulin analogs in Chinese population: Glulisine and Lispro. Endocrine 38(1) 48–52. DOI:10.1007/s12020-010-9326-4 PUBMED:https://pubmed.ncbi.nlm.nih.gov/20960101

  3. Shiramoto, M, et al., & Ohwaki, K (2020). Ultra-Rapid Lispro results in accelerated insulin lispro absorption and faster early insulin action in comparison with Humalog. Journal of diabetes investigation 11(3) 672–680. DOI:10.1111/jdi.13195 PUBMED:https://pubmed.ncbi.nlm.nih.gov/31816193

Parameters

TypeNameDefaultDescription
Modelica.Units.SI.Massweight (from PK_1C)75patient weight (kg)
Modelica.Units.SI.SpecificVolumeVdPerKg (from PK_1C)0.9Volume of distribution (L/kg)
Modelica.Units.SI.MassFractionF (from PK_1C)0.8bioavailiability (0-1)
Pharmacolibrary.Types.ClearanceCl (from PK_1C)20clearance
Modelica.Units.SI.TimeadminTime (from PK_1C)60first administration time (s)
Modelica.Units.SI.TimeadminDuration (from PK_1C)600administration duration (s)
Modelica.Units.SI.TimeadminPeriod (from PK_1C)8*60*60period of administration (default 8 hours)(s)
Pharmacolibrary.Types.MassadminMass (from PK_1C)1000administration mass (mg)
IntegeradminCount (from PK_1C)8number of dose administered (1)
Pharmacolibrary.Types.VolumeVd (from PK_1C)VdPerKg*weightVolume of distribution (m3)
Pharmacolibrary.Types.MassConcentrationCmin (from PK_1C)0.004minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCmax (from PK_1C)0.008minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCtox_peak (from PK_1C)0.012toxicity peak level
Pharmacolibrary.Types.MassConcentrationCtox_trough (from PK_1C)0.006toxicity trough level

Connectors

TypeNameDefaultDescription
Types.ConcentrationOutputC_central (from PK_1C)
Interfaces.ConcentrationPort_bcentralCPort (from PK_1C)

Components

TypeNameDefaultDescription
Pharmacokinetic.NoPerfusedTissueCompartmentcentral (from PK_1C)
Pharmacokinetic.ClearanceDrivenEliminationelim (from PK_1C)
Sources.PeriodicDoseperiodicDose (from PK_1C)
Modelica.Units.SI.Timet1_2 (from PK_1C)elimination half-life

Revisions

  • 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)